
Osimertinib Plus Dato-DXd Shows Efficacy in Post-Osimertinib EGFR-Mutated Advanced NSCLC
The combination of osimertinib (Tagrisso) plus datopotamab deruxtecan (Dato-DXd; Datroway) given at 4 or 6 mg/kg demonstrated encouraging efficacy with acceptable safety in patients with EGFR-mutated non–small cell lung cancer (NSCLC) that had …